Moderna’s mRNA flu shot wins unanimous support at FDA adcomm in rebuke of former leadership

The FDA in February briefly refused to review Moderna’s flu vaccine, citing trial inadequacies, but reversed course a few days later. A verdict is expected by Aug. 5.